Phase 3 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of ovarian, peritoneal, or fallopian tube cancer that has been confirmed through laboratory testing of tissue samples
• People who have completed surgery to remove as much of the tumour as possible (either before or during chemotherapy)
• People who have finished a first course of platinum-based chemotherapy and whose cancer showed a response — including stable disease, partial response, complete response, or no evidence of disease
• People who are able to provide a tumour tissue sample that has not previously been treated with radiation
• People living with HIV, provided their HIV is well-controlled with medication
• People with hepatitis B, provided the virus is undetectable in their blood and they are receiving appropriate antiviral treatment
• People with a history of hepatitis C, provided the virus is currently undetectable in their blood

Who may not be able to join:

• People whose cancer is a non-epithelial type, or falls into certain specific tumour categories including low-grade serous, low-grade endometrioid, borderline, mucinous, seromucinous (mainly mucinous), malignant Brenner's tumour, or undifferentiated carcinoma
• People with known active cancer spread to the brain or spinal fluid
• People with a history of serious eye disease
• People with active inflammatory bowel disease being treated with immune-suppressing medication, or a past history of inflammatory bowel disease
• People with serious, uncontrolled heart or blood vessel disease
• People with a history of non-infectious lung inflammation (pneumonitis) or scarring of the lungs (interstitial lung disease) that required steroid treatment, or who currently have either condition
• People who have received any other systemic cancer treatment beyond the first-line platinum-based chemotherapy required for entry into this trial
• People who have received a live or live-attenuated vaccine within 30 days of joining the trial
• People with another cancer that is still active or required treatment within the past 3 years
• People with an active infection currently requiring treatment with systemic medication
• People with both hepatitis B and hepatitis C infections active at the same time
• People living with HIV who also have a history of Kaposi's sarcoma or multicentric Castleman's disease
• People who have not yet recovered from major surgery, or who have ongoing complications from surgery
• People whose tumour test results from the central laboratory show a positive, unknown, or inconclusive result for a specific genetic marker called homologous recombination deficiency (HRD) (confirm with trial site)
• People with active or ongoing mouth sores (stomatitis) of any severity

Important: Always verify eligibility with the trial site directly before applying.